
    
      In the Phase I portion of the study patients with a diagnosis of AML who have relapsed
      disease will be treated with an assigned number of doses of 5 azacitidine followed by
      Mylotarg administered two times over two weeks

      In the Phase II portion of the study patients will be treated with the dose of 5azacitidine
      determined to be safe in the Phase I portion of the study followed by Mylotarg.

      A sample of blood or bone marrow will be obtained prior to initiation of treatment and
      another sample obtained after treatment with 5-azacitidine but before Mylotarg and the
      samples will be tested in the laboratory to determine response to treatment.
    
  